Humoral and cellular immune response to SARS-CoV-2 mRNA BNT162b2 vaccine in pediatric kidney transplant recipients compared with dialysis patients and healthy children.

Ruveyda Gulmez Doğukan Özbey Ayşe Ağbaş Bagdagul Aksu Nurdan Yıldız Diana Üçkardeş Seha Kamil Saygili Esra Karabag Yilmaz Zeynep Nagehan Yuruk Yildirim Mehmet Tasdemir Ayça Kiykim Haluk Cezmi Cokugras Nur Canpolat Ahmet Nayir Bekir Sami Kocazeybek Salim Caliskan

Published in: Pediatric nephrology (Berlin, Germany) (2022)

The humoral and cellular immune responses to SARS-CoV-2 mRNA BNT162b2 vaccine are lower in pediatric KTRs compared to dialysis patients. Further prospective studies are required to demonstrate the clinical efficacy of the mRNA vaccine in KTRs. This prospective study was registered in ClinicalTrials.gov (NCT05465863, registered retrospectively at 20.07.2022). A higher resolution version of the Graphical abstract is available as Supplementary information.

Keyphrases

immune response
end stage renal disease
sars cov
chronic kidney disease
peritoneal dialysis
ejection fraction
newly diagnosed
prognostic factors
toll like receptor
patient reported outcomes
inflammatory response
patient reported
case control